The medical community is buzzing with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a more substantial l